Seasoned pharmaceutical executive to advise on clinical development, regulatory strategy, and commercialization as Company accelerates its psilocybin-based therapeutic programs BOSTON, May 05, 2025 ...

Increase seen in lifetime use among adults and adolescents; past-year use higher among young adults, older adults.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin ...

The Company is now recognized by the U.S. FDA to support the cross-border supply of GMP MDMA and psilocybin to authorized ...

Colorado lawmakers are considering legislation that would charge the state health agency to collect data and information on ...